Related Experiment Video
Updated: May 30, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S
Alexandru V Olaru1, Gabriel Ghiaur, Sumitaka Yamanaka
1Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MD 21205, USA.
Unlabelled:
MicroRNAs (miRs) recently emerged as prominent regulators of cancer processes. In the current study we aimed at elucidating regulatory pathways and mechanisms through which miR-494, one of the miR species found to be down-regulated in cholangiocarcinoma (CCA), participates in cancer homeostasis. miR-494 was identified as down-regulated in CCA based on miR arrays. Its expression was verified with quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). To enforce miR expression, we employed both transfection methods, as well as a retroviral construct to stably overexpress miR-494. Up-regulation of miR-494 in cancer cells decreased growth, consistent with a functional role. mRNA arrays of cells treated with miR-494, followed by pathway analysis, suggested that miR-494 impacts cell cycle regulation. Cell cycle analyses demonstrated that miR-494 induces a significant G1/S checkpoint reinforcement. Further analyses demonstrated that miR-494 down-regulates multiple molecules involved in this transition checkpoint. Luciferase reporter assays demonstrated a direct interaction between miR-494 and the 3'-untranslated region of cyclin-dependent kinase 6 (CDK6). Last, xenograft experiments demonstrated that miR-494 induces a significant cancer growth retardation in vivo.
Conclusion:
Our findings demonstrate that miR-494 is down-regulated in CCA and that its up-regulation induces cancer cell growth retardation through multiple targets involved in the G1-S transition. These findings support the paradigm that miRs are salient cellular signaling pathway modulators, and thus represent attractive therapeutic targets. miR-494 emerges as an important regulator of CCA growth and its further study may lead to the development of novel therapeutics.
Insights
MicroRNA-494 (miR-494) is down-regulated in cholangiocarcinoma (CCA). Restoring miR-494 levels inhibits cancer cell growth by regulating the G1-S cell cycle transition, offering a potential therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- MicroRNAs (miRs) are key regulators of cellular processes, including cancer.
- Cholangiocarcinoma (CCA) is a cancer where miR-494 expression is found to be reduced.
Purpose of the Study:
- To investigate the role of miR-494 in cholangiocarcinoma (CCA) homeostasis.
- To elucidate the regulatory pathways and mechanisms by which miR-494 influences cancer progression.
Main Methods:
- Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) to verify miR-494 expression.
- Transfection and retroviral methods to overexpress miR-494.
- mRNA arrays, cell cycle analysis, luciferase reporter assays, and xenograft experiments to assess miR-494 function and targets.
Main Results:
- miR-494 was confirmed to be down-regulated in CCA.
- Overexpression of miR-494 inhibited cancer cell growth and induced G1/S cell cycle arrest.
- miR-494 directly targets and down-regulates cyclin-dependent kinase 6 (CDK6).
- In vivo xenograft studies showed significant retardation of tumor growth with miR-494 up-regulation.
Conclusions:
- miR-494 acts as a tumor suppressor in CCA by inhibiting cell cycle progression.
- The findings highlight miR-494 as a crucial regulator of CCA growth and a potential therapeutic target.
- MicroRNAs are significant modulators of cellular signaling pathways with therapeutic implications.
Related Concept Videos
MicroRNAs
MicroRNAs
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Abnormal Proliferation

